Experimental Drug Might Beat Aspirin in Preventing Repeat
WEDNESDAY, Feb. 1 (HealthDay News) -- An investigational drug
called apixaban (Eliquis) appears to be better than aspirin at
preventing blood clots in certain patients who have already
suffered a stroke or so-called "mini-stroke" due to an abnormal
heart rhythm, according to the results of a new study.
For patients with the dangerous irregular heart rhythm known as
atrial fibrillation who can't tolerate the standard drug treatment,
daily apixaban seems to be more effective at warding off a stroke
or blood clot than aspirin, the study found.
The study was funded by Bristol-Myers Squibb and Pfizer, which
are developing apixaban. The findings were slated for presentation
Wednesday at the American Stroke Association's annual conference in
For the study, a team of researchers from Canada and Germany,
led by Dr. Hans-Christoph Diener of the University Hospital Essen,
tracked nearly 5,600 atrial fibrillation patients (average age 70
years) for about one year.
All of the patients were deemed unsuitable for standard
treatment with the anticoagulant known as warfarin (Coumadin), the
researchers pointed out in a news release from the American Stroke
Study participants were randomly divided into two groups: one
group received two daily doses of 5 milligrams of apixaban (part of
a new class of anti-clotting drugs known as Factor Xa inhibitors);
the other group received between 81 and 324 milligrams of aspirin
daily (81 milligrams is a typical "low-dose" aspirin).
The result: among those taking apixaban who had a prior history
of stroke or mini-stroke (transient ischemic attack), only 2.4
percent went on to experience a subsequent stroke or systemic
embolism (blood clot) during treatment. By contrast, that figure
rose to more than 9 percent among similar patients receiving daily
Patients on apixaban had no greater risk of major bleeding than
those on aspirin, the team added.
The researchers concluded that apixaban was well-tolerated and
afforded a greater measure of stroke risk reduction than aspirin
among those for whom warfarin is not a viable option.
Commenting on the findings, Dr. Anthony Comerota, director of
the Jobst Vascular Institute, Toledo Hospital in Toledo, Ohio,
noted that the study results were not surprising, but added that it
is important to understand exactly which patients might benefit
"Because aspirin does not have a major beneficial effect on the blood-clotting system, this is a result that I would expect among those with atrial fibrillation. But this is the point that needs to be made clear: strokes resulting from atrial fibrillation are different from those that result from disease going to the main arteries in the brain," explained Comerota, who was not connected to the study.
"Atrial fibrillation is an abnormal rhythm in the heart, in which the atria -- the top chambers of the heart -- do not contract. They just sort of fibrillate [quiver]. And, therefore, the blood does not empty completely from the atrium. And if it doesn't empty it sits there, and if it sits there stagnant, there's tendency for the blood to clot," he continued.
"So what this study did," Comerota noted, "was compare the benefits of aspirin versus apixaban to reduce the likelihood of this kind of clotting. Clotting in the atrium. Because if
fewer clots form in the heart there's less of a likelihood any will
break off and go to the brain and cause a stroke."
Comerota pointed out that "the benefit of using this new
anticoagulant to reduce this risk is that it comes from a new class
of drugs that has much less interaction than warfarin with other
kinds of medications."
Apixaban does not require the same kind of monitoring as
warfarin, which demands frequent blood tests and also interacts
with many common types of food. "Warfarin is a good drug, but it
needs to be carefully monitored and, unfortunately, has many
problematic interactions. And for those who can't take it, this
study suggests apixaban is a good alternative," Comerota
Apixaban is currently under review for approval by the U.S. Food
and Drug Administration.
The data and conclusions of research presented at medical
meetings should be viewed as preliminary until published in a
For more on atrial fibrillation, visit the
U.S. National Heart, Lung, and Blood
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.